Rice University chemists have discovered a way to load dozens of molecules of the anti-cancer drug paclitaxel onto tiny gold spheres. The result is a tiny ball, many times smaller than a living cell that literally bristles with the drug.

An increase in high-grade prostate cancer among men taking the drug finasteride is likely caused by an increased detection of cancers, and not by the development of more high-grade cancers, according to two studies published online September 11 in the Journal of the National Cancer Institute.

A leading epidemiologist has attacked Swedish research that looked at inequalities in patients’ access to cancer drugs across Europe and the world.

Patients with a particular version of the UGT1A1 gene are at greater risk of neutropenia, a shortage of certain white blood cells, if they are taking medium or high doses of the anticancer drug irinotecan.

Not everyone needs a genetic test before taking the cancer drug irinotecan, and the U.S. Food and Drug Administration should modify its prescription guidelines to say so, according to researchers at the University of North Carolina at Chapel Hill.

Carnegie Mellon University scientists have developed tiny, spherical nanogels that uniformly release encapsulated carbohydrate-based drugs. The scientists created the nanogels using atom transfer radical polymerization (ATRP), which will ultimately enable the nanogels to deliver more drug directly to the target and to dispense the drug in a time-release manner.

An in-depth understanding of the mechanisms that trigger cancer cell growth is vital to the development of more targeted treatments for the disease. An article published in the August 3 issue of Molecular Cell provides a key to these mechanisms that may prove crucial in the future.

Men and their physicians need not hesitate to use a drug proven effective in preventing prostate cancer out of concern that it is likely to cause sexual dysfunction, say authors of a study conducted by the Southwest Oncology Group.

MIT researchers have identified a critical link between two proteins found in brain tumors, a discovery that could eventually help treat a form of brain cancer that kills 99 percent of patients.

A commentary in the Journal of Clinical Oncology (JCO) urges researchers to explore an intriguing approach to reduce the dose, and therefore the cost, of oral targeted cancer therapies.

The annoying bulges of an over-wound telephone cord that shorten its reach and limit a caller’s motion help to explain why drugs called camptothecins are so effective in killing cancer cells, according to investigators at St. Jude Children's Research Hospital and Delft University of Technology.

Based on their surprising discovery that an obesity drug can kill cancer cells, scientists at Wake Forest University School of Medicine have made a new finding about the drug’s effects and are working to design more potent cancer treatments.